Valeant struggling to stay ahead of creditors given ongoing filing delay

Valeant Pharmaceuticals International still hasn’t filed its annual report with the Securities and Exchange Commission and that means the company is squeezed between creditors who can force early repayment of debt for not meeting terms of the loan and investors who want it to get back to business as usual.